AUS
NZ
UK
CA
USA
IND
On July 22, 2026, United Therapeutics Corporation granted Christopher Patusky, a board director, equity compensation comprising stock options and common stock. This transaction, disclosed in a regulatory filing on July 23, 2026, aligns with the company’s standard annual non-employee director compensation. Patusky received 2,380 stock options exercisable at $527.07 per share alongside 2,410 directly acquired common shares.
Key Points
- NASDAQ: UTHR
- Director Christopher Patusky awarded 2,380 stock options and 2,410 common shares on July 22, 2026
- Stock options have an exercise price of $527.07 per share and expire on July 22, 2033
- Options vest on the earlier of the one-year anniversary or the next Annual Meeting of Shareholders, expected June 25, 2027
Overview of Annual Non-Employee Director Equity Compensation
Christopher Patusky’s annual non-employee director award at United Therapeutics includes 2,380 stock options priced at $527.07 each and 2,410 common shares granted without stated consideration. This dual equity compensation approach is a common practice among biopharmaceutical companies to align directors’ interests with those of shareholders.
The equity grant date of July 22, 2026, corresponds with United Therapeutics’ routine director compensation schedule. These awards are structured to promote long-term retention and incentivize directors to support shareholder value creation. The size and vesting terms of the grants are determined by the company’s board compensation committee.
Vesting and Exercise Details for Stock Options
The 2,380 stock options awarded to Patusky expire on July 22, 2033, seven years post-grant. Vesting occurs on the earlier of the one-year anniversary of the grant or the next Annual Meeting of Shareholders, projected for June 25, 2027, which is likely the earlier vesting event.
The exercise price of $527.07 reflects the market value per share at the time of grant, ensuring fair valuation. This vesting schedule provides a clear timeline for option exercise, linking incentive realization to either tenure or key corporate governance milestones.
Role of Christopher Patusky and Board Governance at United Therapeutics
United Therapeutics, a biopharmaceutical company focused on innovative therapies, includes both employee and non-employee directors on its board. Christopher Patusky serves as a non-employee director, contributing independent oversight, strategic guidance, and participation in board committees while remaining separate from daily operations.
Equity compensation for non-employee directors like Patusky incentivizes active governance and alignment with shareholder interests. The combination of stock options and common shares is consistent with industry practices in the biopharmaceutical sector, where director pay typically blends cash retainers with equity awards.
Direct Ownership Status Post-Equity Award
Following the July 22, 2026 transaction, Patusky holds direct beneficial ownership of the 2,410 common shares, granting him immediate legal title and voting rights. The 2,380 stock options are also directly beneficially owned, with exercise rights contingent on vesting conditions.
This direct ownership structure ensures Patusky’s control over voting and exercise decisions, maintaining transparency and regulatory compliance without complex intermediaries.
Regulatory Filing and Section 16 Reporting Compliance
The equity award disclosure was filed under Section 16(a) of the Securities Exchange Act of 1934, which mandates beneficial ownership reporting for directors and officers of public companies. As a director, Patusky is subject to these reporting requirements, confirming his active status at United Therapeutics.
The filing clarifies that this transaction was not executed under a Rule 10b5-1 trading plan, indicating the equity grant was a distinct compensation event approved through the company’s governance processes.
Industry Context and Trends in Director Compensation
Within the biopharmaceutical industry, equity-based compensation for directors is a standard practice due to the sector’s high R&D costs, regulatory demands, and lengthy product development cycles. Directors often bring specialized expertise critical to evaluating strategic and operational initiatives.
Equity awards, such as the options priced at $527.07 per share granted to Patusky, constitute a significant portion of director compensation, reflecting the emphasis on attracting experienced independent board members committed to long-term company success.
Board Compensation Philosophy and Governance Practices
United Therapeutics employs a structured compensation framework differentiating between employee and non-employee directors. The timing of Patusky’s grant aligns with the company’s governance calendar, combining cash retainers and equity awards to balance immediate and long-term incentives.
This compensation model encourages directors to focus on both operational oversight and sustained shareholder value growth, with multi-year option vesting reinforcing long-term alignment.
Authorization and Filing of Beneficial Ownership Disclosure
The beneficial ownership update was executed by John S. Hess, Jr., under power of attorney for Christopher Patusky, and filed on July 23, 2026. Delegating signing authority is a common practice to ensure timely and accurate regulatory compliance without requiring personal execution by directors.
This filing provides formal notification of changes in director equity holdings, fulfilling Securities and Exchange Commission requirements and offering transparency for investors monitoring insider transactions at United Therapeutics.
